BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 22068471)

  • 1. [Recent Advances in α-dystroglycanopathy].
    Kuga A; Kanagawa M; Toda T
    Brain Nerve; 2011 Nov; 63(11):1189-95. PubMed ID: 22068471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Alpha-dystroglycanopathy (FCMD, MEB, etc): abnormal glycosylation and muscular dystrophy].
    Toda T
    Rinsho Shinkeigaku; 2005 Nov; 45(11):932-4. PubMed ID: 16447766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic aspects of the formation of α-dystroglycan and therapeutic research for the treatment of α-dystroglycanopathy: A review.
    Taniguchi-Ikeda M; Morioka I; Iijima K; Toda T
    Mol Aspects Med; 2016 Oct; 51():115-24. PubMed ID: 27421908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan.
    Godfrey C; Clement E; Mein R; Brockington M; Smith J; Talim B; Straub V; Robb S; Quinlivan R; Feng L; Jimenez-Mallebrera C; Mercuri E; Manzur AY; Kinali M; Torelli S; Brown SC; Sewry CA; Bushby K; Topaloglu H; North K; Abbs S; Muntoni F
    Brain; 2007 Oct; 130(Pt 10):2725-35. PubMed ID: 17878207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbohydrate-binding domain of the POMGnT1 stem region modulates O-mannosylation sites of α-dystroglycan.
    Kuwabara N; Manya H; Yamada T; Tateno H; Kanagawa M; Kobayashi K; Akasaka-Manya K; Hirose Y; Mizuno M; Ikeguchi M; Toda T; Hirabayashi J; Senda T; Endo T; Kato R
    Proc Natl Acad Sci U S A; 2016 Aug; 113(33):9280-5. PubMed ID: 27493216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pathomechanism and therapeutic strategy of Fukuyama congenital muscular dystrophy and related disorders].
    Toda T
    Rinsho Shinkeigaku; 2009 Nov; 49(11):859-62. PubMed ID: 20030231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of α-dystroglycan.
    Kuga A; Kanagawa M; Sudo A; Chan YM; Tajiri M; Manya H; Kikkawa Y; Nomizu M; Kobayashi K; Endo T; Lu QL; Wada Y; Toda T
    J Biol Chem; 2012 Mar; 287(12):9560-7. PubMed ID: 22270369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycosylation with ribitol-phosphate in mammals: New insights into the O-mannosyl glycan.
    Manya H; Endo T
    Biochim Biophys Acta Gen Subj; 2017 Oct; 1861(10):2462-2472. PubMed ID: 28711406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and localization of fukutin, POMGnT1, and POMT1 in the central nervous system: consideration for functions of fukutin.
    Yamamoto T; Kato Y; Kawaguchi M; Shibata N; Kobayashi M
    Med Electron Microsc; 2004 Dec; 37(4):200-7. PubMed ID: 15614444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression.
    Ohtsuka Y; Kanagawa M; Yu CC; Ito C; Chiyo T; Kobayashi K; Okada T; Takeda S; Toda T
    Sci Rep; 2015 Feb; 5():8316. PubMed ID: 25661440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
    Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
    Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fukuyama-type congenital muscular dystrophy (FCMD) and alpha-dystroglycanopathy.
    Toda T; Kobayashi K; Takeda S; Sasaki J; Kurahashi H; Kano H; Tachikawa M; Wang F; Nagai Y; Taniguchi K; Taniguchi M; Sunada Y; Terashima T; Endo T; Matsumura K
    Congenit Anom (Kyoto); 2003 Jun; 43(2):97-104. PubMed ID: 12893968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of alpha-dystroglycan.
    Xiong H; Kobayashi K; Tachikawa M; Manya H; Takeda S; Chiyonobu T; Fujikake N; Wang F; Nishimoto A; Morris GE; Nagai Y; Kanagawa M; Endo T; Toda T
    Biochem Biophys Res Commun; 2006 Dec; 350(4):935-41. PubMed ID: 17034757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fukutin and alpha-dystroglycanopathies.
    Toda T; Chiyonobu T; Xiong H; Tachikawa M; Kobayashi K; Manya H; Takeda S; Taniguchi M; Kurahashi H; Endo T
    Acta Myol; 2005 Oct; 24(2):60-3. PubMed ID: 16550916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome.
    Beltrán-Valero de Bernabé D; Currier S; Steinbrecher A; Celli J; van Beusekom E; van der Zwaag B; Kayserili H; Merlini L; Chitayat D; Dobyns WB; Cormand B; Lehesjoki AE; Cruces J; Voit T; Walsh CA; van Bokhoven H; Brunner HG
    Am J Hum Genet; 2002 Nov; 71(5):1033-43. PubMed ID: 12369018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fukutin mutations in non-Japanese patients with congenital muscular dystrophy: less severe mutations predominate in patients with a non-Walker-Warburg phenotype.
    Yis U; Uyanik G; Heck PB; Smitka M; Nobel H; Ebinger F; Dirik E; Feng L; Kurul SH; Brocke K; Unalp A; Özer E; Cakmakci H; Sewry C; Cirak S; Muntoni F; Hehr U; Morris-Rosendahl DJ
    Neuromuscul Disord; 2011 Jan; 21(1):20-30. PubMed ID: 20961758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Congenital muscular dystrophy and alpha-dystroglycanopathy].
    Saito F; Matsumura K; Hagiwara H; Shimizu T
    Rinsho Shinkeigaku; 2008 Aug; 48(8):543-9. PubMed ID: 18939472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Missense mutations in β-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) cause Walker-Warburg syndrome.
    Buysse K; Riemersma M; Powell G; van Reeuwijk J; Chitayat D; Roscioli T; Kamsteeg EJ; van den Elzen C; van Beusekom E; Blaser S; Babul-Hirji R; Halliday W; Wright GJ; Stemple DL; Lin YY; Lefeber DJ; van Bokhoven H
    Hum Mol Genet; 2013 May; 22(9):1746-54. PubMed ID: 23359570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent advances in congenital muscular dystrophy research].
    Nonaka I
    No To Hattatsu; 2005 Mar; 37(2):115-21. PubMed ID: 15773323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycosylation defects: a new mechanism for muscular dystrophy?
    Grewal PK; Hewitt JE
    Hum Mol Genet; 2003 Oct; 12 Spec No 2():R259-64. PubMed ID: 12925572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.